𝔖 Bobbio Scriptorium
✦   LIBER   ✦

841 EFFICACY AND SAFETY OF 2 YEARS MAINTENANCE THERAPY WITH PEGINTERFERON ALPHA-2A IN CHRONIC HEPATITIS C: RESULTS OF A RANDOMIZED CONTROLLED TRIAL (FIBROSYS)

✍ Scribed by J.P. Zarski; N. Sturm; H. Desmorat; P. Melin; J.J. Raabe; C. Bonny; P. Sogni; A. Pinta; S. Rouanet; A. Cheveau; M. Chevallier

Book ID
117376767
Publisher
Elsevier Science
Year
2008
Tongue
English
Weight
72 KB
Volume
48
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Proceed with caution: Peginterferon alph
Proceed with caution: Peginterferon alpha-2a versus peginterferon alfa-2b in chronic hepatitis C. A systematic review of randomized trials
✍ David Kershenobich; Linda Muñoz; René Malé; Jesús Gaytan; Francisco Sánchez 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 379 KB

We read with great interest the article by Cavazza et al., 1 who demonstrated that an advanced histological stage was the only risk factor associated with the development of hepatocellular carcinoma (HCC) in patients with primary biliary cirrhosis (PBC) from two European centers. Similar results wer

Efficacy and safety of peginterferon alp
Efficacy and safety of peginterferon alpha-2a/ribavirin in treatment-naive Cameroonian patients with chronic hepatitis C
✍ Richard Njouom; Michèle Tagni Sartre; Isabelle Timba; Eric Nerrienet; Patrice Tc 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB 👁 1 views

## Abstract Data were examined from a day‐to‐day clinical practice in Yaounde, Cameroon to evaluate the efficacy and safety of peginterferon alfa‐2a and ribavirin in treatment‐naive Cameroonian patients with chronic hepatitis C. Ninety adults with chronic hepatitis C (mean age, 53 ± 8 years; 79% ma